Table of Contents
ISRN Neurology
Volume 2014 (2014), Article ID 861091, 4 pages
http://dx.doi.org/10.1155/2014/861091
Research Article

Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait

1Division of Neurology, Department of Medicine, Amiri Hospital, Arabian Gulf Street, 13041 Kuwait City, Kuwait
2Neurology Clinic, Dasman Diabetes Institute, P.O. Box 1180, 15462 Dasman, Kuwait

Received 3 October 2013; Accepted 20 November 2013; Published 22 January 2014

Academic Editors: A. Karni, Y. Ohyagi, and W. Zhao

Copyright © 2014 S. Lamdhade et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. A. Yousry, E. O. Major, C. Ryschkewitsch et al., “Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy,” The New England Journal of Medicine, vol. 354, no. 9, pp. 924–933, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Bozic, S. Richman, T. Plavina et al., “Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1,” Annals of Neurology, vol. 70, no. 5, pp. 742–750, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Trampe, C. Hemmelmann, A. Stroet et al., “Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort,” Neurology, vol. 78, pp. 1736–1742, 2012. View at Google Scholar
  4. T. Olsson, A. Achiron, L. Alfredsson et al., “Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort,” Multiple Sclerosis, vol. 19, no. 11, pp. 1533–1538, 2013. View at Publisher · View at Google Scholar
  5. R. Alroughani, S. Ahmed, R. Behbahani et al., “Increasing prevalence and incidence rates of multiple 5 sclerosis in Kuwait,” Multiple Sclerosis, 2013. View at Publisher · View at Google Scholar
  6. C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Lee, T. Plavina, A. Castro et al., “A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification,” Journal of Clinical Virology, vol. 57, pp. 141–146, 2013. View at Google Scholar
  8. A. Egli, L. Infanti, A. Dumoulin et al., “Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors,” Journal of Infectious Diseases, vol. 199, no. 6, pp. 837–846, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Antonsson, A. C. Green, K.-A. Mallitt et al., “Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians,” Journal of General Virology, vol. 91, no. 7, pp. 1849–1853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Khalili, M. K. White, F. Lublin, P. Ferrante, and J. R. Berger, “Reactivation of JC virus and development of PML in patients with multiple sclerosis,” Neurology, vol. 68, no. 13, pp. 985–990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Sandrock, C. Hotermans, S. Richman et al., “Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status,” American Academy of Neurolgoy, Poster 03.248, 2011.
  12. L. Gorelik, M. Lerner, S. Bixler et al., “Anti-JC virus antibodies: implications for PML risk stratification,” Annals of Neurology, vol. 68, no. 3, pp. 295–303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Warnke, T. Dehmel, A. Posevitz-Fejfar et al., “Anti-JC-virus antibody prevalence in a German MS cohort,” Multiple Sclerosis, vol. 18, pp. 1054–1055, 2012. View at Google Scholar
  14. A. Achiron, J. Chapman, M. Dolev et al., “Epidemiology of anti-JCV antibodies in israeli multiple sclerosis population (P02.138),” Neurology, vol. 78, P02.138, 2012. View at Google Scholar
  15. C. S. Miller, S. A. Houff, J. Hopper et al., “Disease-modifying drugs for multiple sclerosis and JC virus expression,” Journal of NeuroVirology, vol. 18, pp. 411–415, 2012. View at Google Scholar
  16. P. S. Sørensen, A. Bertolotto, G. Edan et al., “Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab,” Multiple Sclerosis, vol. 18, no. 2, pp. 143–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. Rudick, P. W. O'Connor, C. H. Polman et al., “Assessment of JC virus DNA in blood and urine from natalizumab-treated patients,” Annals of Neurology, vol. 68, no. 3, pp. 304–310, 2010. View at Publisher · View at Google Scholar · View at Scopus